Novo Nordisk A/S (VIE:NNO2)

Market Cap	181.38B -49.4%
Revenue (ttm)	41.38B +6.4%
Net Income	13.72B +1.4%
EPS	3.08 +1.8%
Shares Out	n/a
PE Ratio	13.22
Forward PE	14.46
Dividend	1.56 (3.84%)
Ex-Dividend Date	Aug 15, 2025

Volume	31,291
Average Volume	9,961
Open	41.40
Previous Close	48.88
Day's Range	39.75 - 42.50
52-Week Range	36.00 - 90.35
Beta	n/a
RSI	33.90
Earnings Date	Feb 4, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 78,554
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: NNO2

Financial Performance

In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.

Financial numbers in DKK